
## Ibragim Gaidarov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2835433/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Spatial control of coated-pit dynamics in living cells. Nature Cell Biology, 1999, 1, 1-7.	10.3	386
2	Phosphoinositide–Ap-2 Interactions Required for Targeting to Plasma Membrane Clathrin-Coated Pits. Journal of Cell Biology, 1999, 146, 755-764.	5.2	264
3	The Class II Phosphoinositide 3-Kinase C2α Is Activated by Clathrin and Regulates Clathrin-Mediated Membrane Trafficking. Molecular Cell, 2001, 7, 443-449.	9.7	229
4	Arrestin function in G protein-coupled receptor endocytosis requires phosphoinositide binding. EMBO Journal, 1999, 18, 871-881.	7.8	195
5	Langerhans Cells Release Prostaglandin D2 in Response to Nicotinic Acid. Journal of Investigative Dermatology, 2006, 126, 2637-2646.	0.7	163
6	A Functional Phosphatidylinositol 3,4,5-Trisphosphate/Phosphoinositide Binding Domain in the Clathrin Adaptor AP-2 α Subunit. IMPLICATIONS FOR THE ENDOCYTIC PATHWAY. Journal of Biological Chemistry, 1996, 271, 20922-20929.	3.4	156
7	The Class II Phosphoinositide 3-Kinase PI3K-C2α Is Concentrated in the Trans-Golgi Network and Present in Clathrin-coated Vesicles. Journal of Biological Chemistry, 2000, 275, 11943-11950.	3.4	133
8	G protein–coupled receptor/arrestin3 modulation of the endocytic machinery. Journal of Cell Biology, 2002, 156, 665-676.	5.2	102
9	Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors. Journal of Biological Chemistry, 2007, 282, 18028-18036.	3.4	88
10	Embelin and its derivatives unravel the signaling, proinflammatory and antiatherogenic properties of GPR84 receptor. Pharmacological Research, 2018, 131, 185-198.	7.1	52
11	Individual Phosphoinositide 3-Kinase C2α Domain Activities Independently Regulate Clathrin Function. Journal of Biological Chemistry, 2005, 280, 40766-40772.	3.4	51
12	Kinetics of 5-HT <sub>2B</sub> Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 645-659.	2.5	43
13	Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Medicinal Chemistry Letters, 2014, 5, 1313-1317.	2.8	43
14	Angiotensin (1–7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor. Cellular Signalling, 2018, 50, 9-24.	3.6	43
15	Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potential. Cellular Signalling, 2013, 25, 2003-2016.	3.6	35
16	Phosphoinositide 3-Kinase C2α Links Clathrin to Microtubule-dependent Movement. Journal of Biological Chemistry, 2007, 282, 1249-1256.	3.4	31
17	Major histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of target cells: implications for antigen presentation to cytotoxic T lymphocytes. Immunology, 2004, 113, 460-471.	4.4	29
18	Discovery of APD371: Identification of a Highly Potent and Selective CB <sub>2</sub> Agonist for the Treatment of Chronic Pain. ACS Medicinal Chemistry Letters, 2017, 8, 1309-1313.	2.8	28

IBRAGIM GAIDAROV

#	Article	IF	CITATIONS
19	Discovery of (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension, Journal of Medicinal Chemistry, 2017, 60, 913-927.	6.4	14
20	(7-Benzyloxy-2,3-dihydro- <i>1H</i> -pyrrolo[1,2- <i>a</i> ]indol-1-yl)acetic Acids as S1P <sub>1</sub> Functional Antagonists. ACS Medicinal Chemistry Letters, 2014, 5, 1334-1339.	2.8	12
21	Membrane Targeting of Endocytic Adaptors: Cargo and Lipid Do It Together. Developmental Cell, 2005, 8, 801-802.	7.0	10
22	Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 322-326.	2.2	6